Views and missives from the frontier

July 13, 2021

CAMP4 Therapeutics Expands Leadership and Board of Directors

  • Kelly Gold promoted to Chief Business Officer and SVP, Finance
  • Michelle Gates appointed SVP, Chief People Officer
  • Ravi Thadhani, M.D., M.P.H. named to board of directors


CAMBRIDGE, Mass., July 13, 2021 – CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy gene expression, today announced that it has expanded its leadership team and board of directors as the company continues to develop its platform, programs and internal capabilities. Kelly Gold, who has led CAMP4’s corporate development efforts for the past four years, has been promoted to Senior Vice President (SVP) of Finance and Chief Business Officer and Michelle Gates has been appointed to the newly created role of SVP and Chief People Officer.  Additionally, Ravi Thadhani, M.D., M.P.H., Chief Academic Officer of Mass General Brigham (MGB) and Dean of the Faculty at MGB for Harvard Medical School, will join CAMP4’s board of directors.

“We are putting in place the leadership and advisory expertise that we need to drive our next phase of growth as a company as we build out our RNA Actuating Platform and prosecute multiple preclinical RNA programs in anticipation of entering the clinic next year,” said Josh Mandel-Brehm, CEO of CAMP4. “Kelly has excelled at guiding and executing our corporate development strategy since the very early days of CAMP4 and Michelle is a progressive, creative HR leader with an impressive track record of building high-functioning, collaborative teams at technology-focused companies. Dr. Thadhani’s experience leading a renowned research organization and his prior therapeutic research focus will be highly valuable to our discovery and development efforts, particularly as we explore the vast opportunities before us to enable tunable upregulation of gene expression to treat disease.”

CAMP4 combines its proprietary RNA Actuating Platform (RAP) with state-of-the-art oligonucleotide technology to develop precise and programmable therapeutics that uniquely upregulate gene expression at the transcriptional level. CAMP4’s approach targets a new class of RNA known as regulatory RNAs (“regRNAs”) that control the expression of proteins, making this approach applicable to any genetic disease whereby a small increase in gene output can lead to meaningful therapeutic outcomes. CAMP4’s current pipeline is focused on diseases where oligonucleotides have proven safe and effective, including CNS and liver diseases, with the potential to expand to muscle and heart diseases.

“CAMP4 is at an exciting stage in its evolution as the science and programs are maturing and the company prepares for the transition into the clinic,” said Dr. Thadhani. “I am looking forward to lending my translational and clinical experience to a new field of biology that holds tremendous potential for drug development.”

As Chief Business Officer and SVP, Finance, Ms. Gold is responsible for business development, corporate finance and accounting, investor relations and strategic financial planning. Prior to joining CAMP4, Ms. Gold held various roles in corporate finance and business planning at Biogen, where she provided financial leadership for the company’s late-stage and marketed rare disease programs and developed long-term strategic financial trajectories for the R&D organization. Prior to Biogen, Ms. Gold worked in both the healthcare and Latin American investment banking groups at Deutsche Bank. Ms. Gold began her career as a mechanical engineer designing biocontainment systems for Biosafety Level 4 research facilities. Ms. Gold holds bachelor’s degrees in biochemistry and mechanical engineering from Queen’s University in Ontario, as well as an MBA from the MIT Sloan School of Management.

Ms. Gates joins CAMP4 from a 16-year career at Akamai Technologies, a global content delivery network, cybersecurity and cloud service company. While there, Ms. Gates played a pivotal role in contributing to massive growth and global expansion of the organization, including several acquisitions, and talent driven initiatives that contributed directly to business performance. She was instrumental to the early development and continual transformation of the HR function at Akamai where she led many company-wide programs, built centers of excellence and hired and developed top talent. Ms. Gates has more than 20 years of experience in HR, which includes HR leadership roles at British Telecom and Teradyne, in addition to her time at Akamai. She holds degrees in English and Spanish from Providence College and has completed courses through Wharton’s Executive Education Program.

In his role at MGB, Dr. Thadhani manages a ~$2 billion research enterprise and oversees several key system-wide departments, including Human Subjects Affairs, the Clinical Trials Office, Research Management, the MGB Biobank, and Graduate Medical Education. Dr. Thadhani previously managed a research laboratory for ~25 years, with a focus on kidney disease and developing diagnostics and therapeutics for women with complications in pregnancy. He has published over 300 manuscripts and has been inducted into several honor societies. He is a standing member of the FDA’s Cardio-Renal Division Advisory Panel. Dr. Thadhani has received several distinguished awards including the Harold Amos Faculty Diversity Award from Harvard Medical School, the Alumni Award of Merit from the Harvard T.H. Chan School of Public Health, and the John P. Peters Award from the American Society of Nephrology. Dr. Thadhani received a bachelor’s degree from the University of Notre Dame, a medical degree from the University of Pennsylvania, a master’s in public health from the Harvard T.H. Chan School of Public Health and an online business certificate from the Stanford Graduate School of Business.


About CAMP4 Therapeutics

At CAMP4, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our RNA Actuating Platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Learn more about us at and follow us @CAMP4tx.



Lindy Devereux
Scient PR